Document Detail

Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target.
MedLine Citation:
PMID:  22688525     Owner:  NLM     Status:  In-Data-Review    
Erythropoietin (EPO) is a principal regulator that promotes proliferation and terminal differentiation of erythroid progenitor cells. EPO receptors are expressed not only in hematopoietic lineage cells but also in the cardiovascular system. We performed animal experiments using transgene-rescued EPO receptor null mutant mice (EpoR<sup>-/-</sup><inf>rescued</inf>) that express the EPO receptor exclusively in the hematopoietic cells. The results of these experiments suggest that endogenous EPO/EPO receptor system in the heart exerts cardioprotective effects against myocardial injury induced by ischemia followed by reperfusion and pressure-overload induced left ventricular dysfunction. Many animal experiments have shown that the administration of recombinant human EPO also elicits cardioprotective effects against myocardial injury induced by ischemia and reperfusion. In contrast to the promising results of these animal experiments, recent clinical trials failed to demonstrate the reduction in infarct size or improvement of cardiac function by the administration of recombinant human EPO in patients with acute myocardial infarction who underwent primary percutaneous coronary intervention. It should be tested in future clinical studies whether a relatively low dose of recombinant human EPO or its derivatives that have no erythropoietic action reduces infarct size and ameliorates cardiac dysfunction in patients with acute myocardial infarction. In this article, we review implications of anemia associated with chronic heart failure, roles of the endogenous EPO/EPO receptor system, and the effects of the administration of erythropoiesis-stimulating agents in pathologic conditions of the heart by focusing on the EPO receptor as a potential candidate of novel therapeutic targets in cardiovascular diseases.
Yutaka Kagaya; Yasuhide Asaumi; Wanting Wang; Mo Ihiko Takeda; Makoto Nakano; Kimio Satoh; Yoshihiro Fukumoto; Hiroaki Shimokawa
Related Documents :
974965 - Lithium iodide cardiac pacemakers: initial clinical experience.
8077895 - Acute cholestatic hepatitis and the sudden rise of the pacing threshold 5 weeks after v...
6523495 - Arousal response induced by postural changes in patients with subacute myelo-optico-neu...
25224025 - Evaluation of prognostic scale thrombolysis in myocardial infarction and killip. an st-...
10404845 - Intra-aortic balloon counterpulsation before primary percutaneous transluminal coronary...
7977825 - Heat shock improves ischemic tolerance of hypertrophied rat hearts.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Tohoku journal of experimental medicine     Volume:  227     ISSN:  1349-3329     ISO Abbreviation:  Tohoku J. Exp. Med.     Publication Date:  2012  
Date Detail:
Created Date:  2012-06-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0417355     Medline TA:  Tohoku J Exp Med     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  83-91     Citation Subset:  IM    
Comprehensive Education Center for Community Medicine, Tohoku University Graduate School of Medicine.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Testis-Specific Protein Y-Encoded Copy Number Is Correlated to Its Expression and the Field Fertilit...
Next Document:  Two principal components, coping and independence, comprise patient enablement in Japan: cross secti...